Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07133815 | Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia | PHASE2 | NOT YET_RECRUITING | 55 | — | — | Aug 1, 2025 | Dec 1, 2027 | Aug 21, 2025 | 1 | China |
| Arm | Type | Description |
|---|---|---|
| SHR-1918 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SHR-1918 | DRUG | SHR-1918 |
Inclusion Criteria: 1. Able and willing to provide a written informed consent 2. Subjects who received and completed the SHR-1918-301 study treatment in previous studies and were deemed to have therapeutic benefits by the researchers Exclusion Criteria: 1. Known to be allergic to the investigatio...